Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing and improving deep domain alignment in ultrasound via simulation diversity.

Ultrasonics·2026
Same author

Training-oriented framework for brachytherapy treatment planning in soft tissue sarcoma.

Brachytherapy·2026
Same author

A New Era in Leptomeningeal Disease (LMD): Recent Advancements in Immunocellular and Radiation Therapies in Melanoma LMD, What Has Been Done and Future Directions.

Pigment cell & melanoma research·2026
Same author

Daily Cherenkov Imaging to Monitor for Unintended Field Overlap During Bilateral Breast Radiation Therapy.

Practical radiation oncology·2026
Same author

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Journal of neuro-oncology·2026
Same author

Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2- Metastatic Breast Cancer in the Real-World Setting.

Advances in radiation oncology·2026
Same journal

Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial.

International journal of radiation oncology, biology, physics·2026
Same journal

Proton beam therapy in nonmetastatic rhabdomyosarcoma: Outcome, prognostic factors and the effect of timing of radiation therapy.

International journal of radiation oncology, biology, physics·2026
Same journal

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026
Same journal

Gastrointestinal Motility-Induced Interplay in Pancreas Proton Therapy: Motion Simulation and Dosimetric Impact.

International journal of radiation oncology, biology, physics·2026
Same journal

Intra-fractional Voxel-wise Anatomical Motion Tracking Guided by Multimodal Respiratory Surrogates in Radiotherapy: Framework Development and Multi-Center Validation.

International journal of radiation oncology, biology, physics·2026
Same journal

A Gaussian-based planning approach for robust dose-escalated stereotactic body proton therapy.

International journal of radiation oncology, biology, physics·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K

Neoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal Sarcoma.

Casey L Liveringhouse1, Russell F Palm1, John M Bryant1

  • 1Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

International Journal of Radiation Oncology, Biology, Physics
|March 19, 2023
PubMed
Summary
This summary is machine-generated.

Neoadjuvant simultaneous integrated boost (SIB) radiation therapy (RT) improves abdominopelvic control and recurrence-free survival in retroperitoneal sarcoma (RPS) patients. This advanced RT technique enhances disease control without increasing toxicity compared to standard techniques.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Related Experiment Videos

Last Updated: Aug 6, 2025

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Retroperitoneal sarcoma (RPS) treatment remains challenging, with standard neoadjuvant radiation therapy (RT) offering limited benefits.
  • The high-risk region (HRR) in RPS, prone to positive surgical margins and recurrence, necessitates targeted dose escalation.
  • Simultaneous integrated boost (SIB) RT allows for dose escalation to the HRR while sparing surrounding radiosensitive organs.

Purpose of the Study:

  • To investigate the efficacy of neoadjuvant SIB RT in improving disease control for patients with retroperitoneal sarcoma (RPS).
  • To compare the outcomes of SIB RT with standard techniques (ST) in terms of abdominopelvic control (APC), recurrence-free survival (RFS), and overall survival (OS).
  • To assess the toxicity profile associated with neoadjuvant SIB RT compared to ST in RPS patients.

Main Methods:

  • Retrospective analysis of 103 patients with resectable, nonmetastatic RPS treated between 2000 and 2021.
  • Patients received either standard volume neoadjuvant RT (ST) or neoadjuvant SIB RT with dose escalation to the HRR.
  • Clinical endpoints included APC, RFS, OS, and acute toxicity, with a median follow-up of 57 months.

Main Results:

  • SIB RT was associated with a significant improvement in 5-year APC (96% vs. 70%, P=.046) and RFS (60.2% vs. 36.3%, P=.036) compared to ST.
  • Multivariable analysis confirmed SIB as an independent predictor for improved APC and RFS.
  • SIB RT demonstrated a lower rate of grade 3 acute toxicity (3% vs. 22%, P=.023) compared to ST, with no significant detriment.

Conclusions:

  • Neoadjuvant SIB RT in RPS is independently associated with improved abdominopelvic control and recurrence-free survival.
  • Dose escalation using SIB RT offers potential benefits over standard RT techniques without increasing toxicity.
  • Future prospective studies are warranted to further evaluate the benefits of SIB RT in RPS management.